newsfilter
← Latest News
Business Wire·

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Presentations span ceftobiprole and zoliflodacin, highlighting post-approval evidence generation across antimicrobial-resistant and difficult-to-treat infections Innoviva Specialty Therapeutics (IST), a subsidiary of